1.Identification of efficacy predictive genes long-term responding to anti-α4β7 integrins in ulcerative colitis patients
Yonghao CHEN ; Baizhou PAN ; Xi CHENG ; Shichu LIANG ; Lingyu CHANG ; Qiao MEI
Chinese Journal of Inflammatory Bowel Diseases 2021;05(4):314-320
Objective:To identify the co-expressed different expressed genes (DEGs) related to long-term responding in patients receiving vedolizumab or etrolizumab, whose expression could be tested to indicate the treatment efficacy when taking anti-α4β7 integrins.Methods:Two datasets were downloaded from Gene Expression Omnibus (GEO) to be analyzed. Limma, Gene Ontology (GO) and KEGG analysis were used to screen DEGs and possible pathways. The most significant module in the PPI networks was analyzed by Cytoscape. ROC curves were built to indicate the predictive potential.Results:A total of 433 DEGs were found between patients′ response and non-response to vedolizumab, and 15 DEGs between patients received vedolizumab and etrolizumab. The GO and KEGG analyses showed overlaps were enriched to some immune-related pathways closely matched to the mechanism of anti-integrins. Eight hub genes were distinguished from the PPI network: MNDA, AQP9, FPR1, FCGR3B, VNN2, TREM1, MYO1F and GAS2L3 (5 of them had been identified to be related to IBD in labs) . Conclusions:Efficacy of anti-α4β7 intergins is closely associated with inflammation-related and adhesion-related genes. The possible hub genes and related pathways are distinguished, which can be used as potential long-term response indicators towards suitable patients receiving anti-integrins.
2.Identification of efficacy predictive genes long-term responding to anti-α4β7 integrins in ulcerative colitis patients
Yonghao CHEN ; Baizhou PAN ; Xi CHENG ; Shichu LIANG ; Lingyu CHANG ; Qiao MEI
Chinese Journal of Inflammatory Bowel Diseases 2021;05(4):314-320
Objective:To identify the co-expressed different expressed genes (DEGs) related to long-term responding in patients receiving vedolizumab or etrolizumab, whose expression could be tested to indicate the treatment efficacy when taking anti-α4β7 integrins.Methods:Two datasets were downloaded from Gene Expression Omnibus (GEO) to be analyzed. Limma, Gene Ontology (GO) and KEGG analysis were used to screen DEGs and possible pathways. The most significant module in the PPI networks was analyzed by Cytoscape. ROC curves were built to indicate the predictive potential.Results:A total of 433 DEGs were found between patients′ response and non-response to vedolizumab, and 15 DEGs between patients received vedolizumab and etrolizumab. The GO and KEGG analyses showed overlaps were enriched to some immune-related pathways closely matched to the mechanism of anti-integrins. Eight hub genes were distinguished from the PPI network: MNDA, AQP9, FPR1, FCGR3B, VNN2, TREM1, MYO1F and GAS2L3 (5 of them had been identified to be related to IBD in labs) . Conclusions:Efficacy of anti-α4β7 intergins is closely associated with inflammation-related and adhesion-related genes. The possible hub genes and related pathways are distinguished, which can be used as potential long-term response indicators towards suitable patients receiving anti-integrins.
Result Analysis
Print
Save
E-mail